Tiny needle patch takes aim at skin cancer

NCT ID NCT05377905

Recruiting now Disease control Sponsor: Falo, Louis, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a small adhesive patch with tiny needles that deliver a low dose of the chemotherapy drug doxorubicin directly into skin cancer tumors. It involves 48 people with squamous cell skin cancer who are either immune-competent or immune-suppressed. The goal is to see if the patch is safe and can clear the tumor under and around it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: doxorubicin delivered via a microneedle patch
What this could lead to: If it works, this could offer a less invasive, targeted treatment for skin cancer that avoids systemic chemo side effects.
What could go wrong: This is an early-phase trial with only 48 participants, so results may not apply broadly. The patch only treats the area under it, and cancer may still recur elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS SQUAMOUS CELL CARCINOMA SKIN CANCERS - SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.